Update relating to LEQEMBI® from Eisai’s investor presentation of their quarterly report published today
Stockholm, Sweden, November 7, 2023 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today held a presentation on the second quarter of Eisai’s fiscal year, ending March 2024. In addition to presenting sales numbers of 0.4 billion yen for LEQEMBI for the period, Eisai also stated the following;· The launch of LEQEMBI in the U.S. is progressing as planned and the company reiterated their expectation that 10,000 patients will be on LEQEMBI by the end of March 2024 · The number of neurologists or other Alzheimer disease (AD) specialists who are ready to diagnose, treat and